Leerink Partners analyst Geoffrey Porges reiterated an Outperform rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III DataApril 1, 2016 11:52 AM Roth Expects Full Approval of Regeneron (REGN) Dupilumab, Trims PT to $520 April 1, 2016 10:55 AM Regeneron (REGN), Sanofi (SNY)Announce Two Dupilumab Phase 3s Met Primary Endpoint in Atopic DermatitisApril 1, 2016 6:57 AM Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis PatientsApril 1, 2016 1:00 AM